Amplitude Ventures
Amplitude Ventures is a venture capital firm based in Montreal, Canada, specializing in early-stage investments within the biotechnology and healthcare sectors. Founded in 2018, the firm focuses on supporting emerging Canadian companies, leveraging a growth model that has proven effective in developing world-class management teams and scaling businesses to achieve significant growth. Amplitude Ventures has raised over $700 million in equity capital since its inception and launched its first private capital fund in November 2019, targeting precision medicine companies. The firm operates additional offices in Toronto and Vancouver, and its latest fund, established in 2023, aims to invest in various sectors, including diagnostic equipment, therapeutic devices, drug delivery, and biotechnology, across Canada, the United States, and Europe.
InVivo AI is a Montreal-based company founded in 2017 that specializes in using artificial intelligence to enhance pharmaceutical research and development. The company primarily focuses on preclinical toxicology, aiming to improve the efficiency and effectiveness of drug development processes. By leveraging advanced AI technologies, InVivo AI seeks to transform traditional methodologies in the pharmaceutical industry, ultimately contributing to faster and more reliable outcomes in drug safety assessments.
Clementia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Montreal, Canada, focused on developing innovative treatments for patients with ultra-rare bone disorders and other diseases characterized by high unmet medical needs. Founded in 2010, the company specializes in disease-modifying therapies, with its lead product candidate being palovarotene, an oral small molecule. Palovarotene has demonstrated significant potential in preventing abnormal bone formation and fibrosis across various tissues. The candidate is currently undergoing evaluation in the Phase III MOVE trial, targeting conditions such as fibrodysplasia ossificans progressive and multiple osteochondromas, as well as dry eye disease. Clementia's commitment to addressing debilitating health issues highlights its role in advancing treatment options for affected patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.